IDX 21459

Drug Profile

IDX 21459

Alternative Names: IDX21459

Latest Information Update: 24 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Idenix Pharmaceuticals
  • Class Antivirals; Uracil nucleotides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 24 Sep 2014 Discontinued - Phase-I for Hepatitis C in Canada (PO)
  • 24 Sep 2014 Discontinued - Phase-I for Hepatitis C in Europe (PO)
  • 01 Aug 2014 Idenix terminates phase I trial in Hepatitis C in Europe and Canada (NCT02112942)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top